Ernexa Therapeutics Inc. (ERNA) Balance Sheet

The consistent decline in total assets suggests that the company is consuming its capital base to fund ongoing R&D without replenishing it through operations or successful financing. This trajectory indicates a business model that is currently unable to sustain its own existence, leaving the balance sheet increasingly fragile.

While the reduction in debt improves the D/E ratio, it likely reflects the exhaustion of credit facilities or the conversion of debt into equity during periods of distress. Investors should monitor whether the company retains any meaningful access to debt markets, as the current low leverage may simply mask a total lack of financing capacity.

The current ratio of 1.01 in 2025Q4 highlights a precarious liquidity position where current assets barely cover immediate obligations. This lack of a meaningful cash buffer leaves the company highly vulnerable to any operational delays or unexpected expenses, potentially forcing management into dilutive capital raises.

The accumulation of a $251.1 million deficit in retained earnings as of 2026Q1 illustrates the massive value destruction that has occurred over the company's history. Future equity quality remains highly suspect, as any path to recovery likely requires substantial dilution that would further diminish the value of existing shares.